Last reviewed · How we verify
Open Label (OL) Paroxetine
Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Open Label (OL) Paroxetine |
|---|---|
| Also known as | Paxil |
| Sponsor | VA Office of Research and Development |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
As a selective serotonin reuptake inhibitor (SSRI), paroxetine blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The drug is used to treat depression, anxiety disorders, and other conditions associated with serotonin dysregulation.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia
- Somnolence
- Tremor
- Sweating
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Open Label (OL) Paroxetine CI brief — competitive landscape report
- Open Label (OL) Paroxetine updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI